These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 35158466)

  • 41. Gut microbiota composition as a candidate risk factor for dimethyl fumarate-induced lymphopenia in multiple sclerosis.
    Diebold M; Meola M; Purushothaman S; Siewert LK; Pössnecker E; Roloff T; Lindberg RL; Kuhle J; Kappos L; Derfuss T; Egli A; Pröbstel AK
    Gut Microbes; 2022; 14(1):2147055. PubMed ID: 36398902
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Safety and efficacy of dimethyl fumarate in multiple sclerosis: a multi-center observational study.
    Miclea A; Leussink VI; Hartung HP; Gold R; Hoepner R
    J Neurol; 2016 Aug; 263(8):1626-32. PubMed ID: 27260297
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Dimethyl fumarate associated lymphopenia in clinical practice.
    Longbrake EE; Cross AH
    Mult Scler; 2015 May; 21(6):796-7. PubMed ID: 25432948
    [No Abstract]   [Full Text] [Related]  

  • 44. Cross-sectional analysis of peripheral blood mononuclear cells in lymphopenic and non-lymphopenic relapsing-remitting multiple sclerosis patients treated with dimethyl fumarate.
    Lee CH; Jiang B; Nakhaei-Nejad M; Barilla D; Blevins G; Giuliani F
    Mult Scler Relat Disord; 2021 Jul; 52():103003. PubMed ID: 34118574
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effectiveness and Safety of Dimethyl Fumarate Treatment in Relapsing Multiple Sclerosis Patients: Real-World Evidence.
    Alroughani R; Ahmed SF; Behbehani R; Al-Hashel J
    Neurol Ther; 2017 Dec; 6(2):189-196. PubMed ID: 28780745
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Increased NK Cell Count in Multiple Sclerosis Patients Treated With Dimethyl Fumarate: A 2-Year Longitudinal Study.
    Marastoni D; Buriani A; Pisani AI; Crescenzo F; Zuco C; Fortinguerra S; Sorrenti V; Marenda B; Romualdi C; Magliozzi R; Monaco S; Calabrese M
    Front Immunol; 2019; 10():1666. PubMed ID: 31379857
    [No Abstract]   [Full Text] [Related]  

  • 47. CMV meningitis associated with dimethyl fumarate therapy-induced lymphopenia in a multiple sclerosis patient.
    Kogel AK; Gold R; Schneider R
    J Neurol; 2021 Nov; 268(11):4374-4375. PubMed ID: 34175973
    [No Abstract]   [Full Text] [Related]  

  • 48. Persisting lymphopenia and dimethyl fumarate: A clinical commentary.
    Diem L; Chan A
    Mult Scler; 2021 Jul; 27(8):1309-1310. PubMed ID: 33620267
    [TBL] [Abstract][Full Text] [Related]  

  • 49. PML during dimethyl fumarate treatment of multiple sclerosis: How does lymphopenia matter?
    Lehmann-Horn K; Penkert H; Grein P; Leppmeier U; Teuber-Hanselmann S; Hemmer B; Berthele A
    Neurology; 2016 Jul; 87(4):440-1. PubMed ID: 27343070
    [No Abstract]   [Full Text] [Related]  

  • 50. Dimethyl fumarate-associated lymphopenia: Risk factors and clinical significance.
    Longbrake EE; Naismith RT; Parks BJ; Wu GF; Cross AH
    Mult Scler J Exp Transl Clin; 2015; 1():. PubMed ID: 26550483
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Lymphocyte reconstitution after DMF discontinuation in clinical trial and real-world patients with MS.
    Chan A; Rose J; Alvarez E; Bar-Or A; Butzkueven H; Fox RJ; Gold R; Gudesblatt M; Haartsen J; Spelman T; Wright K; Ferraro D; Sola P; Hodgkinson S; Kalincik T; Lechner-Scott J; McGuigan C; Spach K; Chen C; Fam S; Wu F; Miller C
    Neurol Clin Pract; 2020 Dec; 10(6):510-519. PubMed ID: 33510947
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Lymphopenia in Multiple Sclerosis patients treated with Ocrelizumab is associated with an effect on CD8 T cells.
    Abbadessa G; Maida E; Miele G; Lavorgna L; Marfia GA; Valentino P; De Martino A; Cavalla P; Bonavita S
    Mult Scler Relat Disord; 2022 Apr; 60():103740. PubMed ID: 35305426
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Safety of dimethyl fumarate for multiple sclerosis: A systematic review and meta-analysis.
    Liang G; Chai J; Ng HS; Tremlett H
    Mult Scler Relat Disord; 2020 Nov; 46():102566. PubMed ID: 33296968
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Real-life persistence and tolerability with dimethyl fumarate.
    Sejbaek T; Nybo M; Petersen T; Illes Z
    Mult Scler Relat Disord; 2018 Aug; 24():42-46. PubMed ID: 29906666
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Fingolimod vs dimethyl fumarate in multiple sclerosis: A real-world propensity score-matched study.
    Prosperini L; Lucchini M; Haggiag S; Bellantonio P; Bianco A; Buscarinu MC; Buttari F; Centonze D; Cortese A; De Giglio L; Fantozzi R; Ferraro E; Fornasiero A; Francia A; Galgani S; Gasperini C; Marfia GA; Millefiorini E; Nociti V; Pontecorvo S; Pozzilli C; Ruggieri S; Salvetti M; Sgarlata E; Mirabella M
    Neurology; 2018 Jul; 91(2):e153-e161. PubMed ID: 29875218
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Different Fumaric Acid Esters Elicit Distinct Pharmacologic Responses.
    Wipke BT; Hoepner R; Strassburger-Krogias K; Thomas AM; Gianni D; Szak S; Brennan MS; Pistor M; Gold R; Chan A; Scannevin RH
    Neurol Neuroimmunol Neuroinflamm; 2021 Mar; 8(2):. PubMed ID: 33468560
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Safety and Efficacy of Dimethyl Fumarate in Multiple Sclerosis: An Italian, Multicenter, Real-World Study.
    Mirabella M; Prosperini L; Lucchini M; Boffa L; Borriello G; Buscarinu MC; Centonze D; Cortese A; De Fino C; De Giglio L; Elia G; Fantozzi R; Ferraro E; Francia A; Galgani S; Gasperini C; Haggiag S; Landi D; Marfia GA; Millefiorini E; Monteleone F; Nociti V; Salvetti M; Sgarlata E; Pozzilli C
    CNS Drugs; 2018 Oct; 32(10):963-970. PubMed ID: 30022464
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies.
    Havrdova E; Giovannoni G; Gold R; Fox RJ; Kappos L; Phillips JT; Okwuokenye M; Marantz JL
    Eur J Neurol; 2017 May; 24(5):726-733. PubMed ID: 28328179
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparative effectiveness using a matching-adjusted indirect comparison between delayed-release dimethyl fumarate and fingolimod for the treatment of multiple sclerosis.
    Fox RJ; Chan A; Zhang A; Xiao J; Levison D; Lewin JB; Edwards MR; Marantz JL
    Curr Med Res Opin; 2017 Feb; 33(2):175-183. PubMed ID: 27733070
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Three-Year Effectiveness of Dimethyl Fumarate in Multiple Sclerosis: A Prospective Multicenter Real-World Study.
    Pilo de la Fuente B; Sabín J; Galán V; Thuissard I; Sainz de la Maza S; Costa-Frossard L; Gómez-Moreno M; Díaz-Díaz J; Oreja-Guevara C; Lozano-Ros A; García-Domínguez JM; Borrego L; Ayuso L; Castro A; Sánchez P; Meca-Lallana V; Muñoz C; Casanova I; López de Silanes C; Martín H; Rodríguez-García E; Andreu-Vázquez C; Blasco R; García-Merino JA; Aladro Y;
    CNS Drugs; 2020 Dec; 34(12):1275-1286. PubMed ID: 33226562
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.